The MRCF is an innovative investment collaboration which invests in life science opportunities from its member medical research institutes and their associated hospitals throughout Australia. Established in 2007, investment funding from the MRCF is available to promising opportunities from its 50 member institutes.
Counsel and Investment
The MRCF provides its member institutes with commercialisation advice and access to risk tolerant investment funds for proof-of-principle experiments as well as for the formation of new companies. The objective of the MRCF Collaboration is to help each participating Institute with the commercialisation of their intellectual property through a structured funding process to realise its commercial value. Promising biotech, medical device or diagnostics technologies at the seed stage can receive up to $3 million in funding. Successful MRCF portfolio companies can receive a further $10-15 million of investment from the MRCF.
The MRCF has AUD$251 million under investment. The MRCF funds comprise:
- The AUD$200 million MRCF3. This fund is supported by AustralianSuper, Statewide Super, HESTA and HOSTPLUS.
- The AUD$40 million MRCF IIF, LP. A Venture Capital Limited Partnership (VCLP) established under an Innovation Investment Fund (IIF) license (Round 3) from the Commonwealth of Australia (now fully invested).
- The AUD$11 million MRCF Trust (now fully invested).
Board of Directors
The MRCF collaboration has an independent Board of Directors comprising: Hon. Alan Stockdale (Chair), Denise Allen, Hon. Peter Beattie, Winsome Hall, Ross King, and Wayne McMaster.
The MRCF collaboration values the financial support it receives from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.
If you are interested in accessing the MRCF, please contact your commercialisation office for details of the application process, or for more information please visit www.mrcf.com.au.